Neidhöfer Claudio, Rathore Kamni, Parčina Marijo, Sieber Martin A
Institute of Medical Microbiology, Immunology and Parasitology, University Hospital Bonn, Venusberg-Campus 1, 53127 Bonn, Germany.
Institute for Functional Gene Analytics, Bonn-Rhein-Sieg University of Applied Sciences, 53757 Sankt Augustin, Germany.
Antibiotics (Basel). 2023 May 8;12(5):871. doi: 10.3390/antibiotics12050871.
Combatting the rapidly growing threat of antimicrobial resistance and reducing prevalence and transmission of ESKAPEE pathogens in healthcare settings requires innovative strategies, one of which is displacing these pathogens using beneficial microorganisms. Our review comprehensively examines the evidence of probiotic bacteria displacing ESKAPEE pathogens, with a focus on inanimate surfaces. A systematic search was conducted using the PubMed and Web of Science databases on 21 December 2021, and 143 studies were identified examining the effects of and spp. cells and products on the growth, colonization, and survival of ESKAPEE pathogens. While the diversity of study methods limits evidence analysis, results presented by narrative synthesis demonstrate that several species have the potential as cells or their products or supernatants to displace nosocomial infection-causing organisms in a variety of in vitro and in vivo settings. Our review aims to aid the development of new promising approaches to control pathogen biofilms in medical settings by informing researchers and policymakers about the potential of probiotics to combat nosocomial infections. More targeted studies are needed to assess safety and efficacy of different probiotic formulations, followed by large-scale studies to assess utility in infection control and medical practice.
应对迅速增长的抗菌药物耐药性威胁，并降低医疗环境中ESKAPEE病原体的流行率和传播，需要创新策略，其中之一是利用有益微生物取代这些病原体。我们的综述全面研究了益生菌取代ESKAPEE病原体的证据，重点关注无生命表面。2021年12月21日，我们使用PubMed和Web of Science数据库进行了系统检索，共识别出143项研究，这些研究考察了 和 菌属的细胞及产物对ESKAPEE病原体生长、定植和存活的影响。虽然研究方法的多样性限制了证据分析，但叙述性综述呈现的结果表明，几种菌属作为细胞或其产物或上清液，有潜力在多种体外和体内环境中取代引起医院感染的生物体。我们的综述旨在通过向研究人员和政策制定者通报益生菌对抗医院感染的潜力，帮助开发新的、有前景的方法来控制医疗环境中的病原体生物膜。需要开展更具针对性的研究来评估不同益生菌制剂的安全性和有效性，随后进行大规模研究以评估其在感染控制和医疗实践中的效用。
